All pages

Extracorporeal support systems have kept premature lambs developing for weeks, pointing toward partial ectogenesis for extreme prematurity — a long way from full gestation.

Self-experimentation should be judged by reversibility, measurement quality, downside planning, and evidence strength.

BCIs connect neural activity to computers, prosthetics, and communication systems, with medical restoration leading enhancement.

Partial reprogramming aims to restore youthful cell function without erasing identity or triggering uncontrolled growth.

Attempts to boost focus, memory, or mood with drugs, supplements, and stimulation are common, but robust enhancement in healthy people is weaker than the marketing suggests.

Preserving a legally dead body at very low temperature in hope of future revival is unproven, cannot be tested on current timelines, and depends on assumptions about technologies that do not exist.

Next-generation prosthetics combine robotics, neural control, sensory feedback, and adaptive software.

Community and self-experimental biology puts once-specialized tools in more hands, offering genuine access benefits alongside real safety and biosecurity concerns.

Screening IVF embryos for common-disease risk scores is commercially available, but the predicted benefits are small, uncertain, and ethically contested.

Living cells engineered to fight disease have transformed some blood cancers and are being pushed toward solid tumors, autoimmunity, and off-the-shelf manufacturing.

DNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.

CRISPR, base editing, prime editing, and epigenetic editing expand what medicine can rewrite, regulate, or silence.

Editing embryos, eggs, or sperm would make genetic changes heritable. The technical barriers are serious and the ethical and governance barriers are, for now, decisive.

A shared framework that organizes aging into interconnected biological processes, giving longevity research a common map of what to measure and target.

Sharing a young circulatory environment rejuvenates some tissues in animals, but the human versions — young plasma or plasma dilution — remain unproven and easy to oversell.

Making eggs and sperm from ordinary cells would upend reproduction — it has produced healthy pups in mice, but a safe human version does not yet exist.

Editing genes inside the body has moved from concept to approved therapy, and delivery — not the editor — is now the dominant constraint on what can be treated.

Aging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.

Programmable nanoscale devices — often built from DNA — can carry drugs and release them on a molecular cue, with early tumor-targeting demonstrations in animals.

Techniques to weaken, strengthen, or even implant memories work in animals and hint at trauma treatments, but human memory engineering is early and ethically fraught.

Swapping faulty mitochondria to prevent inherited mitochondrial disease has produced babies under strict regulation — a narrow, heritable germline intervention.

Rapamycin extends lifespan in multiple animal models by inhibiting mTOR, making it the most reproducible pharmacological longevity signal — and a live question for human healthspan trials.

NAD+ declines with age and is central to energy metabolism and repair, but whether raising it with precursors produces meaningful healthspan benefit in humans remains unsettled.

Stimulating the brain with implanted or external devices is established therapy for some conditions — and a contested tool for enhancement.

Programmable RNA platforms can compress the path from molecular insight to tailored therapy, especially for rare or rapidly changing targets.

Psilocybin and MDMA paired with therapy show promise for depression and PTSD in trials, but regulatory approval, durability, and trial design remain unsettled.

Organoids, bioprinting, xenotransplantation, and perfusion systems are converging on the bottleneck of organ replacement.

Sensory implants are the most mature human-machine interfaces: cochlear implants restore useful hearing at scale, while retinal prostheses show how hard vision remains.

Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context.

Embryo-like structures grown from stem cells let scientists study early development without eggs or sperm — powerful research tools that outrun existing rules.

Engineered cells and biological circuits could sense disease, manufacture therapies, and adapt inside the body.

Instead of blocking a protein, degraders instruct the cell to destroy it — expanding the range of disease targets beyond what traditional inhibitors can reach.

Continuous sensing turns the body into a data stream. The value depends on whether measurements are accurate, actionable, and paired with a decision — not on the data alone.

The idea of scanning and simulating a brain in enough detail to reproduce its function is a long-horizon concept with no experimental pathway in humans and deep unknowns about what would be captured.

Clusters of frog cells can be shaped into tiny programmable organisms that move, heal, and even replicate kinematically — an early proof that living tissue can be engineered into machines.

Gene-edited pig organs have kept human recipients alive for weeks to months, opening a possible route around the chronic shortage of human donor organs.